Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET

Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ("Opus" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.

The Company also plans to present the full clinical dataset and additional analyses from the OPGx-BEST1 program at several upcoming medical conferences.